Evidence map›Paper›PMID 40408016›Full record

ArticleEJNMMI research2025

Radiation protection considerations with [

Adnan Chowdhury, Clément Morgat, Clement Bailly, John Sunderland, Stephen A Graves, Andrew M Scott, Sean Baker, Beverley F Holman

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03849118 (A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03849118 phase3completednot on this map

A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses

TypeinterventionalSponsorTelix Pharmaceuticals (Innovations) Pty LimitedRan2019 to 2022Enrolled300ConditionsClear Cell Renal Cell CarcinomaArms89Zr-girentuximab
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Adnan ChowdhuryRoyal Free London NHS Foundation Trust, London, UK.
Clément MorgatINCIA UMR 5287, University of Bordeaux, 33400, Talence, France.
Clement BaillyNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes, France.
John SunderlandDepartment of Radiology, University of Iowa, Iowa City, IA, USA.
Stephen A GravesDepartment of Radiology, University of Iowa, Iowa City, IA, USA.
Andrew M ScottDepartment of Molecular Imaging and Therapy, Austin Health and Faculty of Medicine, University of Melbourne, Melbourne, Australia.
Sean BakerRoyal Free London NHS Foundation Trust, London, UK.
Beverley F HolmanRoyal Free London NHS Foundation Trust, London, UK. beverley.holman@nhs.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

resultsThe maximum dose rate from a vial with no shielding was 0.334 µSv/h/MBq, and the minimum dose rate with 66 mm lead shielding was 0.004 µSv/h/MBq. The controlled spill measured 0.52 µSv/h/MBq. Dose rates 1 m from patients who received [

conclusionsOur results demonstrate low radiation exposure levels associated with CLINICAL TRIAL NUMBER: not applicable for this study; ZIRCON trial number NCT03849118, registered on 19 February 2019.

Indexed as

GirentuximabRadiation protectionRadiation safetyRadiopharmaceuticalsZirconium-89

Identifiers

PMID40408016
PMCPMC12102418

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.